News
MBX
32.45
-8.23%
-2.91
LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)
TipRanks · 1h ago
MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge
Simply Wall St · 2d ago
MBX Biosciences price target raised to $56 from $50 at Stifel
TipRanks · 3d ago
MBX Biosciences Is Maintained at Overweight by Barclays
Dow Jones · 4d ago
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70
Benzinga · 4d ago
MBX Biosciences Is Maintained at Market Outperform by Citizens
Dow Jones · 4d ago
Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86
Benzinga · 4d ago
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
TipRanks · 4d ago
Stifel Nicolaus Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)
TipRanks · 4d ago
MBX BIOSCIENCES INC <MBX.O>: BARCLAYS RAISES TARGET PRICE TO $70 FROM $66
Reuters · 4d ago
MBX BIOSCIENCES INC <MBX.O>: STIFEL RAISES TARGET PRICE TO $56 FROM $50
Reuters · 4d ago
MBX Biosciences price target raised to $70 from $66 at Barclays
TipRanks · 4d ago
MBX Biosciences price target raised to $86 from $76 at Citizens
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and MBX Biosciences, Inc. (MBX)
TipRanks · 4d ago
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
Reuters · 4d ago
MBX Biosciences price target raised to $70 from $50 at Truist
TipRanks · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Barrick Mining, Lumentum, Tesla
Reuters · 4d ago
BUZZ-MBX rises on obesity drug data showing monthly dosing potential
Reuters · 5d ago
MBX Biosciences Price Target Raised to $70.00/Share From $50.00 by Truist Securities
Dow Jones · 5d ago
MBX Biosciences Is Maintained at Buy by Truist Securities
Dow Jones · 5d ago
More
Webull provides a variety of real-time MBX stock news. You can receive the latest news about MBX Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.